- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01824602
Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder
February 26, 2014 updated by: Bial - Portela C S.A.
Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder in a Double-blind, Fixed Multiple Dose, Randomised, Placebo-controlled,Multicentre Clinical Trial.
The primary study objective was to evaluate the dose-dependent efficacy of eslicarbazepine acetate administered at doses of 600, 1200, and 1800 mg over a 3-week period, compared with placebo, as therapy in patients with acute mania.
The secondary objectives of this study were to a) evaluate the safety and tolerability of eslicarbazepine acetate (BIA 2-093) administered at doses of 600, 1200, and 1800 mg compared with placebo, b) assess the duration to onset of action in the different dose groups, and c) monitor the appearance of depressive symptoms.
Study Overview
Status
Terminated
Conditions
Detailed Description
This was a phase II, double-blind, fixed multiple dose, randomised, placebo-controlled, multicentre clinical trial in patients with a diagnosis of bipolar I disorder who experienced an acute manic (including mixed) episode.
Patients who met the selection criteria at randomisation visit (V) (V2, Day 1) were randomised to 1 of 4 treatment groups: 600, 1200, or 1800 mg eslicarbazepine acetate, or placebo.
Patients started the assigned treatment on Day 1 and were followed for up to 3 weeks.
On Day 10, patients who showed no improvement were switched to open-label escape therapy with an established antimanic therapy.
Patients could have been hospitalized at screening or at any time during the study at the investigator's discretion.
Following randomisation (V2, Day 1), patients were assessed on Days 3, 7, 10, 14, 21, 28, and 56, after which they could either enter a recurrence prevention study, or the study drug could be tapered off and they could undergo follow-up assessments.
Study Type
Interventional
Enrollment (Actual)
38
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Aged 18 years or more.
- A documented diagnosis of bipolar I disorder according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria (i.e., 296.0, 296.4 or 296.6).
- Currently displaying an acute manic (including mixed) episode according to the DSM-IV criteria.
- A Young Mania Rating Scale (YMRS) total score of 20 or greater.
- Symptoms of the current manic episode starting within 2 weeks prior to Randomization (V2, Day 1).
- Able to undergo a standard evaluation, including clinical interview, ratings and laboratory studies.
- Signed informed consent form (ICF).
- Post-menopausal or otherwise incapable of becoming pregnant by reason of surgery or tubal ligation. In case of woman of childbearing potential, patient presents a serum pregnancy test consistent with a non-gravid state and will use double-barrier contraception until at least the post-study visit (PSV).
Exclusion Criteria:
- History of schizophrenia or schizoaffective disorder, psychotic features or rapid cycling.
- Currently treated with carbamazepine or oxcarbazepine.
- History of unresponsiveness, intolerance or hypersensitivity to related compounds (carbamazepine, oxcarbazepine or licarbazepine).
- Use of any depot-neuroleptics for the current manic episode
- Abuse of stimulating drugs or use of any systemic sympathicomimetic drug within the previous 2 weeks.
- Electroconvulsive therapy (ECT) within the previous 3 months
- History of dependence or chronic abuse from alcohol, drugs or medications within the last year.
- Judged clinically to be at risk of harm to self or others.
- Second or third-degree atrioventricular blockade not corrected with a pacemaker.
- Relevant ECG or laboratory abnormalities.
- Calculated creatinine clearance <30 ml/min [men: (140-age) x weight / serum creatinine x 72; women: (0.85) (140-age) x weight / serum creatinine x 72. Age in years, weight in kg, and serum creatinine in mg/dl].
- Pregnancy or nursing.
- Participation in other drug clinical trial within the last 2 months before Randomization visit
- Not ensured capability to perform the trial or to comply with the study protocol (e.g. mental retardation or severe inability to communicate);
- Any other uncontrolled clinically relevant disorder.
- Previous treatment with Eslicarbazepine Acetate.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1
Eslicarbazepine acetate 1800 mg
|
Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
Other Names:
|
Experimental: Group 2
Eslicarbazepine acetate 1200 mg
|
Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
Other Names:
|
Experimental: Group 3
Eslicarbazepine acetate 600 mg
|
Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
Other Names:
|
Placebo Comparator: Group 4
Placebo pills
|
Placebo sugar pills
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Young Mania Rating Scale (YMRS) Total Score From Baseline Until the End of the 3-week Treatment Period
Time Frame: baseline and 3-week
|
The YMRS is used to assess disease severity in patients who have been previously diagnosed with mania and it has proven psychometric properties through 11 item multiple-choice diagnostic questionnaire and the total score is determined from the summation of each 11 individual scores (and can range from 0 - 60) based on the patient's subjective feedback of his clinical condition over the previous 48 hours.
A higher score indicates a worse rating for symptoms related to mania.
At every visit throughout the study, investigators administered the YMRS.
The results of the primary analysis of efficacy were calculated using Analysis of covariance (ANCOVA) with Last Observation Carried Forward (LOCF).
Primary variable is presented through ANCOVA results for absolute change in YMRS total score from baseline (V2) to end of treatment (V7).
A responder has at least 50% improvement (reduction) in the YMRS total score or has a total score of less than 12 points at the end of treatment period.
|
baseline and 3-week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Patrício Soares-da-Silva, MD, PhD, BIAL - Portela & Ca. SA
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2006
Primary Completion (Actual)
November 1, 2006
Study Completion (Actual)
November 1, 2006
Study Registration Dates
First Submitted
March 28, 2013
First Submitted That Met QC Criteria
April 2, 2013
First Posted (Estimate)
April 5, 2013
Study Record Updates
Last Update Posted (Estimate)
March 27, 2014
Last Update Submitted That Met QC Criteria
February 26, 2014
Last Verified
August 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BIA-2093-204
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on BIPOLAR I DISORDER
-
ProgenaBiomeRecruitingBipolar Disorder | Bipolar I Disorder | Bipolar II Disorder | Bipolar Type I Disorder | Bipolar Disorder Mild | Bipolar Disorder Moderate | Bipolar Disorder SevereUnited States
-
Rush University Medical CenterThe Ryan Licht Sang Bipolar FoundationCompletedBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar Disorder I | Bipolar Affective DisorderUnited States
-
Otsuka Pharmaceutical Development & Commercialization...H. Lundbeck A/SCompletedBipolar I DisorderUnited States, Taiwan, Romania, Korea, Republic of, Japan, Poland, Canada
-
Professor Saad ShakirMerck Sharp & Dohme LLCCompletedBipolar I DisorderUnited Kingdom
-
Solvay PharmaceuticalsWyeth is now a wholly owned subsidiary of Pfizer; H. Lundbeck A/SCompleted
-
University of Sao PauloCompleted
-
University of Sao PauloUnknown
-
Merck Sharp & Dohme LLCRecruitingBipolar I DisorderUnited States
-
Roxane LaboratoriesCompletedBipolar I DisorderUnited States
-
Eli Lilly and CompanyCompletedBipolar I DisorderUnited States
Clinical Trials on Eslicarbazepine acetate 1800 mg
-
SunovionCompletedEpilepsyUnited States, Bulgaria, Czech Republic, Serbia, Ukraine
-
Bial - Portela C S.A.SunovionCompletedPartial EpilepsyUnited States, Argentina, Germany, France, Belgium, Canada, Italy, Poland, Greece, Brazil, Cyprus
-
Bial - Portela C S.A.Completed
-
Bial - Portela C S.A.Completed
-
Bial - Portela C S.A.Completed
-
Bial - Portela C S.A.Completed
-
Bial - Portela C S.A.Completed
-
Bial - Portela C S.A.Terminated
-
Bial - Portela C S.A.Completed
-
Bial - Portela C S.A.CompletedEpilepsySpain, Bulgaria, Austria, Croatia, Czechia, France, Germany, Poland, Portugal, Romania